Alterity Therapeutics (ATHE) Accumulated Expenses (2014 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Accumulated Expenses of $89173.9 for Q2 2025, down 18.52% year-over-year from $109439.6 in Q2 2024, and down 18.52% quarter-over-quarter from $109439.6 in Q2 2024.
Alterity Therapeutics (ATHE) Accumulated Expenses (2014 - 2025) Analysis & Trends
Alterity Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $89173.9 for Q2 2025.
- In Q2 2025, Accumulated Expenses fell 18.52% year-over-year to $89173.9; the TTM figure through Jun 2025 stood at $89173.9 (down 18.52% YoY), while the FY2025 annual figure was $89173.9, down 18.52% from the prior year.
- Accumulated Expenses for Q2 2025 stood at $89173.9, down from $109439.6 in the prior quarter.
- The five-year high for Accumulated Expenses was $109439.6 in Q2 2024, with the low at $89173.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 89,173.92 |
| Jun 30, 2024 | 109,439.58 |
| Dec 31, 2015 | 55,652.20 |
| Dec 31, 2014 | 79,194.76 |